Anti-complementary Activity of Several Dimethyltin Carboxylates and Dimethyltin Carboxylates and Dimethyltin Dichloride Complexes with Various Donor Ligands

Abstract

The anti-complementary activities have been evaluated in vitro (using
a test that detects complement proteins inhibition) for several dimethyltin
carboxylates of the general formula Me₂SnX₂ [X = 1/2O₂(CO)₂ (oxalate),
1/2O₂(CO)₂CH₂ (malonate), 1/2O₂(CO)₂CH=CH (maleate), 1/2O₂(CO)₂
C—CH₂CH₂CH₂ (cyclobutyl dicarboxylate), O(CO)C₆H₁₁ (cyclobutyl
carboxylate) and O(CO)CMe₃ (pivolate)] and dimethyltin dichloride complexes
of the general formula Me₂SnCl₂.L [L = 8-hydroxy quinoline (L1),
8-hydroxy quinoline-N-oxide (L2), 2,6-diaminopyridine (L3), cyclohexyl
amine (L4), (1R, 2R)-1,2-cyclohexane diamine (L5), 3,5-dimethylpyrazole
(L6), harmaline (L7) and harmine (L8)]. The results obtained have been
compared with those of the three known anticancer drugs (cisplatin, carboplatin
and oxaliplatin) and with that of the starting material
Me₂SnCI₂. Three of the tin compounds displayed remarkable anti-complementary
activities (IC₅₀≤ 0.1 μg mL^-1) which are almost similar to those
of the drugs and tenfolds better than that of Me₂SnCl₂
(IC₅₀ = 1.0  μg mL ^-1).